InvestorQ : What is the latest on the ongoing war of words between Serum Institute and Bharat Biotech over the vaccine approvals by DCGI?
Sam Eswaran made post

What is the latest on the ongoing war of words between Serum Institute and Bharat Biotech over the vaccine approvals by DCGI?

Answer
image
Moii Chavate answered.
2 weeks ago
Follow

It looks like there is finally peace between the two key players in the COVID vaccine initiative in India. A day after the stand-off between Serum Institute and Bharat Biotech over the Covaxin approval, both companies agreed to cooperate and work together. They have agreed that the first priority would be handle medical logistics projects of inoculation.

DCGI had given Emergency Usage approval or EUA to Serum Institute’s Covishield and Bharat Biotech’s Covaxin. Covishield was jointly developed by Oxford Research and AstraZeneca and will be produced and distributed by Serum Institute of India. Covaxin is indigenous made along with National Institute of Virology and the Indian Council for Medical Research or ICMR.

The dispute began when Covaxin managed to get an approval even without conducting Phase-3 trials. As a result, Bharat Biotech could not publish the efficacy ratio. The reason the DCGI did not approve the Pfizer vaccine was that it required refrigeration at beyond -50 degrees centigrade, which was not feasible. Covaxin and Covishield only require regular refrigeration.

2 Views